Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST ...

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST ...

GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time modifier gene therapy for all ABCA4 -associated retinopathies

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with

Release - Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - Channelchek

Open the article to view the coverage from channelchek.com

Ocugen Completes Dosing Ahead of Schedule in Pivotal Stargardt Disease Gene Therapy Trial

Key Takeaways Ocugen completed dosing ahead of schedule in its phase 2/3 GARDian3 trial for OCU410ST, a one-time gene therapy candidate for Stargardt disease The study enrolled 63 patients across a broad age and disease spectrum, with early data expected in Q3 2026 and a planned BLA submission in mid-2027 OCU410ST has shown a favorable safety profile so far and aims to slow retinal degeneration and preserve vision in patients with ABCA4-associ…